SCHEMBL13610975

SCHEMBL13610975

COC1CN(C(=O)OC(C)(C)C)CC[C@H]1CNC(=O)c1cc(C)cc2c1OCCCO2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
PKM P14618 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
EED O75530 1/20 0.37
RBBP4 Q09028 1/20 0.37
SUZ12 Q15022 1/20 0.37
EZH2 Q15910 1/20 0.37
AEBP2 Q6ZN18 1/20 0.37
TP53 P04637 2/20 0.36
MAPT P10636 2/20 0.36
THRB P10828 1/20 0.36
USP30 Q70CQ3 2/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
UTS2R Q9UKP6 2/20 0.36
SCN9A Q15858 1/20 0.36
LMNA P02545 1/20 0.35
ACKR3 P25106 1/20 0.35
GPR119 Q8TDV5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13603113 1.00 KDM4E (0.38) KDM4EPKMMEN1KMT2AEED
SCHEMBL13610960 0.91 KDM4E (0.39) KDM4EPKMMEN1KMT2AEED
SCHEMBL13603119 0.91 KDM4E (0.39) KDM4EPKMMEN1KMT2AEED
SCHEMBL13315487 0.91 KDM4E (0.39) KDM4EPKMMEN1KMT2AEED
SCHEMBL13603114 0.91 KDM4E (0.39) KDM4EPKMMEN1KMT2AEED
SCHEMBL13611212 0.91 KDM4E (0.39) KDM4EPKMMEN1KMT2AEED
SCHEMBL13603112 0.89 CETP (0.36) KDM4EPKMMEN1KMT2AMAPT
SCHEMBL13611211 0.89 CETP (0.36) KDM4EPKMMEN1KMT2AMAPT
SCHEMBL13603095 0.87 KDM4E (0.41) KDM4EPKMMEN1KMT2AEED
SCHEMBL13600605 0.85 IL1B (0.39) KDM4EPKMMEN1KMT2AEED

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638535-B2 (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity JANSSEN PHARMACEUTICA N.V. (BE) 2009-12-29 US disclosed